Open Access

Ulrike Leiter, Markus V. Heppt, Theresa Steeb, Mareike Alter, Teresa Amaral, Andrea Bauer, Falk G. Bechara, Jürgen C. Becker, Eckhard W. Breitbart, Helmut Breuninger, Thomas Diepgen, Thomas Dirschka, Thomas Eigentler, A. K. Stephan El Gammal, Moritz Felcht, Michael J. Flaig, Markus Follmann, Klaus Fritz, Stephan Grabbe, Rüdiger Greinert, Ralf Gutzmer, Axel Hauschild, Uwe Hillen, Stephan Ihrler, Swen Malte John, Lukas Kofler, Oliver Koelbl, Albrecht Krause-Bergmann, Klaus Kraywinkel, Steffen Krohn, Thomas Langer, Carmen Loquai, Christoph R. Löser, Peter Mohr, Dorothée Nashan, Monika Nothacker, Christina Pfannenberg, Carmen Salavastru, Lutz Schmitz, Eggert Stockfleth, Rolf-Markus Szeimies, Claas Ulrich, Susanne Voelter-Mahlknecht, Dirk Vordermark, Michael Weichenthal, Julia Welzel, Kai Wermker, Susanne Wiegand, Claus Garbe, Carola Berking

• Actinic keratosis (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guideline “actinic keratosis and cutaneous squamous cell carcinoma” was updated and expanded by the topics cutanepus squamous cell carcinoma in situ (Bowen’s disease) and actinic cheilitis. This guideline was developed at the highest evidence level (S3) and is aimed at dermatologists, general practitioners, ear nose and throat specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings, as well as other medical specialties, policy makers and insurance funds involved in the diagnosis and treatment of patients with AK and cSCC.